NCT05177653View on ClinicalTrials.gov

Separate and Combined Extrapancreatic Effects of the Incretin Hormones

NACompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

April 7, 2022

Primary Completion Date

March 3, 2023

Study Completion Date

March 3, 2023

Conditions
Pancreatectomy; Hyperglycemia
Interventions
OTHER

Intravenous infusion

GIP receptor antagonist (GIP(3-30)NH2)

OTHER

Intravenous infusion

GLP-1 receptor antagonist (exendin(9-39)NH2)

OTHER

Intravenous infusion

GIP(3-30)NH2 and exendin(9-39)NH2

OTHER

Intravenous infusion

Saline

Trial Locations (1)

2900

Center for Clinical Metabolic Research, Hellerup

All Listed Sponsors
lead

University Hospital, Gentofte, Copenhagen

OTHER